doi: 10.3389/fnut.2022.861750 Received 25 January 2022 Accepted 29 March 2022 Published 26 April 2022 Volume 9 - 2022 Edited by Hui-Xin Liu, China Medical University, China Reviewed by Xingen Lei, Cornell University, United States
With the aforementioned current legal backdrop, there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product as the market continues to evolve, even if the company has not historically focused on tirzepatide as a compound, Leerink analyst Michael Cherny wrote in the note
Its convenient, easy to follow, and may aid short-term weight loss, though its long-term success hasnt been studied
Plants 26, 233245
Your diabetes team will help you find the right dosing
Its a direct path to restoring your B12 levels and feeling your best